Kyverna Therapeutics, Inc.
No SEC Form 4 filings for $KYTX in the last 30 days.
See all $KYTX insider activity →Kyverna Therapeutics (KYTX) reported promising Phase 1 trial data for miv-cel in progressive multiple sclerosis, showing sustained clinical benefits and robust CAR T-cell penetration in the CNS. The treatment demonstrated a well-tolerated safety profile and received RMAT designation for non-active secondary progressive MS, with a development update expected by early 2027.
Kyverna Therapeutics (KYTX) reported 1-year data from its KYSA-8 trial, showing sustained clinical benefit and deep B-cell depletion with miv-cel in stiff person syndrome. The treatment had a well-tolerated safety profile, with no high-grade CRS or ICANS reported. The data confirms earlier signals of efficacy and safety, with potential for FDA review and approval.
Kyverna Therapeutics (KYTX) will present 1-year SPS trial results and updated MS data at MSToronto2026. The company expects to complete its rolling BLA for miv-cel in SPS this quarter, according to the announcement.
Over the past 7 days, AlphAI's AI scored 8 news stories mentioning KYTX (Kyverna Therapeutics, Inc.). Coverage has skewed bullish: 8 bullish, 0 neutral, and 0 bearish.
Recent KYTX coverage spans technology, financial news and regulation.
Positive trial data may lift KYTX stock as investors anticipate further development and potential regulatory milestones.
Positive trial data suggests strong efficacy and safety, likely prompting investor optimism.
Positive trial data and imminent BLA filing could drive significant upside.
Positive trial data may lift KYTX as investors price in potential FDA approval and first‑in‑class CAR‑T therapy for autoimmune disease.
Positive Phase 2 data may lift KYTX as investors see a clear path to BLA filing.
AlphAI scores every news story that mentions KYTX with an AI model for sentiment and relevance, and aggregates insider trades from Kyverna Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Kyverna Therapeutics (KYTX) reported promising Phase 1 trial data for miv-cel in progressive multiple sclerosis, showing sustained clinical benefits and robust CAR T-cell penetration in the CNS. The treatment demonstrated a well-tolerated safety profile and received RMAT designation for non-active secondary progressive MS, with a development update expected by early 2027.
2 min readKyverna Therapeutics (KYTX) reported 1-year data from its KYSA-8 trial, showing sustained clinical benefit and deep B-cell depletion with miv-cel in stiff person syndrome. The treatment had a well-tolerated safety profile, with no high-grade CRS or ICANS reported. The data confirms earlier signals of efficacy and safety, with potential for FDA review and approval.
2 min readKyverna Therapeutics (KYTX) will present 1-year SPS trial results and updated MS data at MSToronto2026. The company expects to complete its rolling BLA for miv-cel in SPS this quarter, according to the announcement.
1 min readKyverna Therapeutics (KYTX) will present data at MSToronto2026 showing sustained benefits and a well-tolerated safety profile for its CAR T-cell therapy, miv-cel, in stiff person syndrome and progressive multiple sclerosis. The company expects to complete its BLA submission for SPS this quarter, potentially leading to the first approved treatment for the condition.
2 min readKyverna Therapeutics advances in autoimmune CAR T therapy despite setbacks at Novartis and Bristol Myers Squibb. Novartis paused trials after patient deaths, and BMS halted trials due to safety concerns. Kyverna's mivocabtagene autoleucel (miv-cel) shows promise in stiff person syndrome with a solid safety profile. The company aims to complete a BLA filing by year-end.
3 min readKyverna Therapeutics (KYTX) reported positive one-year data for miv-cel, showing durable responses and favorable safety in stiff person syndrome and generalized myasthenia gravis. The company plans to complete its BLA submission for SPS by Q4 2026 and finish Phase 3 enrollment for gMG by mid-2027. KYTX stock is up 8.63% in pre-market trading.
1 min readKyverna Therapeutics (KYTX) shares rose 10% after reporting positive one-year data for miv-cel therapy in stiff person syndrome and generalized myasthenia gravis. The therapy showed sustained benefits and a well-tolerated safety profile. The company plans to complete a rolling BLA submission by Q4 2026.
2 min readKyverna Therapeutics (KYTX) stock rose 8.1% pre-market after reporting positive 1-year data from its KYSA-8 trial for stiff person syndrome and encouraging long-term results from the KYSA-6 trial for generalized myasthenia gravis. The company plans to submit these results to the FDA by Q4 2026. Analysts have a 'Strong Buy' consensus with a $30.40 average price target.
2 min readKyverna Therapeutics reported 1-year data for miv-cel, showing sustained efficacy and no high-grade safety issues in SPS and gMG trials. The company plans to submit this data to the FDA, keeping it on track for a Q4 application. Meanwhile, competitors Novartis and Bristol Myers Squibb faced safety setbacks in their autoimmune CAR-T trials.
3 min readKyverna Therapeutics, Inc. (KYTX) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis Topline durability data reinforce potential for single-dose miv-cel to fre
2 min read
